Loading...
•
Dec 31, 2020
CorMedix Q4 2020 Earnings Report
CorMedix reported a net loss for the fourth quarter of 2020, driven by increases in employee and market research costs. The company is focused on bringing DefenCath to hemodialysis patients.
Key Takeaways
CorMedix reported a net loss of $6.1 million for the fourth quarter of 2020, compared to a net loss of $5.3 million in the fourth quarter of 2019. The increase in net loss was primarily driven by increases in employee costs and market research costs. The company had $46.3 million in cash and short-term investments as of December 31, 2020.
CorMedix recorded a net loss of $6.1 million, or $0.19 per share, in Q4 2020.
Operating expenses for Q4 2020 were $6.1 million.
The company believes it has sufficient resources to fund operations at least into the second half of 2022.
CorMedix is focused on developing DefenCath for the prevention of bloodstream infections associated with central venous catheters.
Forward Guidance
CorMedix believes that, based on the Company’s cash resources at year end plus the $41.5 million in net proceeds from ATM issuances since the beginning of 2021, it has sufficient resources to fund operations at least into the second half of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...